Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways

Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathwaysПодробнее

Ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosisПодробнее

Emerging Agents Pacritinib and Momelotinib for MFПодробнее

Upcoming Therapies for Use in MPNПодробнее

Safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosisПодробнее

PACIFICA: Phase III study of pacritinib vs BAT in patients with MF and severe thrombocytopeniaПодробнее

SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment in R/R MF?Подробнее

The value of pacritinib in the treatment of MFПодробнее

How JAK Inhibitors Work!Подробнее

Dr. Rampal on Ongoing Research With Pacritinib in MyelofibrosisПодробнее

Treatment of Myelofibrosis: Emerging TherapiesПодробнее

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?Подробнее

New therapies for MPNsПодробнее

Updates on the use of momelotinib for the treatment of MF & clinical trials evaluating this agentПодробнее

Recent updates from the MOMENTUM trial and the value of momelotinib for the treatment of MFПодробнее

Pacritinib moves foward in MF: PAC2013 and PACIFICAПодробнее

Fedratinib in MF: JAKARTA2 and FREEDOM TrialsПодробнее

Risk-adjusted safety analysis of pacritinib for patients with MFПодробнее

Safety of full dose pacritinib versus BAT in patients with cytopenic myelofibrosisПодробнее

Results of PERSIST-1 & PERSIST-2 studies of pacritinib vs best alternative therapy in myelofibrosisПодробнее